Quantcast

Latest photodynamic therapy Stories

2010-07-28 00:06:21

NYU Langone Medical Center has begun a clinical trial offering vascular-targeted photodynamic therapy to patients with localized prostate cancer. This novel, minimally invasive procedure uses a light-activated drug to deliver light energy waves by way of laser fibers in order to destroy prostate cancer cells. "This minimally invasive technique for localized prostate cancer offers the potential to destroy the cancer without making any incision or causing any potentially devastating sexual,...

2010-06-24 05:30:00

All Claims Upheld at Conclusion of Successful Reexamination Process WILMINGTON, Mass., June 24 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office (USPTO) has completed its re-examination of US Patent No. 5,079,262, "Method of detection and treatment of malignant and...

2010-05-13 11:04:00

WILMINGTON, Mass., May 13 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (Nasdaq: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, today announced that its Annual Meeting of Shareholders will be held on Thursday, July 29, 2010 at 11:00 AM at the Company's offices at 25 Upton Drive, Wilmington, MA. The Company also reported that...

2010-05-11 08:30:00

TSX Venture: QPT EDMONTON, May 11 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052...

2010-05-11 05:30:00

WILMINGTON, Mass., May 11 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the first quarter ended March 31, 2010. Highlights for the first quarter include: Total product revenues were $8.7 million for...

2010-05-07 05:30:00

WILMINGTON, Mass., May 7 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office has issued a notice of allowance for a key patent related to its proprietary PDT light source, the BLU-U(®), Blue Light Photodynamic Therapy Illuminator. The new patent will have...

2010-04-29 07:59:00

MONACO, April 29, 2010 /PRNewswire/ -- At the 10th Congress of the European Society for Photodynamic Therapy (Euro PDT), held in Monaco on March 12-13, 2010, Professor Lasse Braathen (Tromso, Norway), president of the Euro PDT, described the current state of topical photodynamic therapy, a revolutionary treatment for precancerous skin lesions and superficial skin carcinomas. He also underscored the major role played by the Euro PDT, whose objective is to promote research, development, and...

2010-03-09 07:30:00

WILMINGTON, Mass., March 9 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (Nasdaq: DUSA), a specialty pharmaceutical company focused primarily on the development and marketing of its Levulan(®) Photodynamic Therapy (PDT) technology platform for the prevention and treatment of dermatological skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Roth 22nd Annual OC Growth Stock...

2010-03-05 06:00:00

WILMINGTON, Mass., March 5 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(® )(NASDAQ GM: DUSA), a specialty pharmaceutical company focused on dermatology, will unveil an ergonomically enhanced BLU-U(®) Blue Light Photodynamic Therapy Illuminator at this year's American Academy of Dermatology (AAD) meeting in Miami, Florida, March 5-9. BLU-U, in conjunction with the Levulan(®) Kerastick(® )topical treatment, is an...

2010-03-03 05:30:00

WILMINGTON, Mass., March 3 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the fourth quarter and full year ended December 31, 2009. Fourth quarter and full year financial highlights include: The...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related